Standout Papers

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory A... 2017 2026 2020 2023 447
  1. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma (2017)
    Frederick L. Locke, Sattva S. Neelapu et al. Molecular Therapy

Immediate Impact

1 by Nobel laureates 9 from Science/Nature 62 standout
Sub-graph 1 of 21

Citing Papers

Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial
2025 Standout
Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy
2024 Standout
2 intermediate papers

Works of Meg Elias being referenced

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
2017 Standout

Author Peers

Author Last Decade Papers Cites
Meg Elias 520 127 87 149 149 15 551
Jeff Aycock 573 141 93 155 168 24 607
Christina A. Bachmeier 496 114 136 123 117 27 571
Danielle Vanasse 481 129 50 184 136 7 520
Bindu George 396 131 52 152 102 19 509
Fenlu Zhu 464 142 42 174 119 20 567
Elizabeth Halton 536 123 46 116 186 29 584
Stephanie Rawlings-Rhea 415 83 21 133 107 14 464
Yueh-wei Shen 445 206 24 186 113 13 591
Ian R. Hardy 410 158 58 179 103 10 538
Mohamed-Reda Benmebarek 557 240 24 198 142 17 634

All Works

Loading papers...

Rankless by CCL
2026